Skip to content

Effect of Sivelestat Sodium as an Add-On Therapy on Perihematomal Edema Volume and Neurological Functional Outcomes in Patients with Intracerebral Hemorrhage: A Single-Center, Prospective, Randomized Controlled Clinical Study

Effect of Sivelestat Sodium as an Add-On Therapy on Perihematomal Edema Volume and Neurological Functional Outcomes in Patients with Intracerebral Hemorrhage: A Single-Center, Prospective, Randomized Controlled Clinical Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122007
Enrollment
Unknown
Registered
2026-04-08
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spontaneous Intracerebral Hemorrhage

Interventions

Sponsors

First Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age greater than 18 years and less than 80 years; 2. Confirmed by computed tomography as acute intracerebral hemorrhage; 3. Hospitalized within 24 hours after the onset of intracerebral hemorrhage; 4. GCS score > 5 points or NIHSS score < 21 points upon admission.

Exclusion criteria

Exclusion criteria: 1. Hemorrhage definitively attributed to trauma, aneurysm, or tumoral stroke (i.e., non-spontaneous intracerebral hemorrhage). 2. Presence of intraventricular extension of the hematoma. 3. Scheduled for surgical hematoma evacuation. 4. History of significant pre-existing disability (modified Rankin Scale score >3). 5. Severe renal disease (i.e., renal dysfunction requiring dialysis) or estimated glomerular filtration rate (eGFR) 3 times the upper limit of normal (ULN) or total bilirubin >2 times ULN. 7. Pregnancy or lactation. 8. Acute ST-elevation myocardial infarction, decompensated heart failure, cardiac arrest, acute coronary syndrome, or known acute coronary syndrome, acute myocardial infarction, or coronary intervention within the past 3 months. 9. Treatment with Sivelestat Sodium for acute lung injury/COPD within the past 7 days. 10. Known hypersensitivity or allergy to Sivelestat Sodium. 11. Life expectancy less than 3 months due to conditions other than the current intracerebral hemorrhage. 12. Concurrent participation in another interventional clinical trial involving investigational drug therapy.

Design outcomes

Primary

MeasureTime frame
Adverse functional outcomes at 90 days after onset;

Secondary

MeasureTime frame
The absolute volume of the hematoma (unit: mL) on the 3rd and 7th day after the onset of the disease and the changes from the baseline.;Parameters of pericerebral edema on days 3 and 7 after onset: including absolute volume (PHE), relative volume (rPHE), edema spread distance (EED), peak volume and rate of increase, etc.;Pneumonia incidence during hospitalization;

Countries

China

Contacts

Public ContactYang Guang

First Affiliated Hospital of Harbin Medical University

yangguang@hrbmu.edu.cn+86 187 4607 2927

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026